Seeking Alpha·1d ago
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
Corvus Pharmaceuticals is a clinical-stage biotech with no revenue and a rapidly accelerating cash burn, with quarterly operating losses expanding 206% from $6.3M in 2024Q1 to $19.3M in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.22-14.3% vs -$0.19 | — vs — |
Q3 2026 Aug 6, 2026 | -$0.19-19.4% vs -$0.16 | — vs — |
Q2 2026 May 7, 2026 | -$0.15-7.1% vs -$0.14 | — vs — |
Q2 2026 Mar 12, 2026 | -$0.15-7.1% vs -$0.14 | — vs $775,000 |
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call Transcript
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib.
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety profile consistent with results from soquelitinib T cell lymphoma and atopic dermatitis clinical trials SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that initial data from a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 12-15, 2026 in New Orleans, LA.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 5, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2026 financial results.
Benchmark CRVS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Corvus Pharmaceuticals, Inc. (CRVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.54 | $886.31M | -15.16 | — | — | -34.98% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $4.37 | $177.42M | 8.17 | 55.25% | 58.87% | 6.24% | 23.45% | |
| $1.73 | $123.77M | -1.00 | — | — | -48.58% | — | |
| $2.29 | $254.25M | 6.15 | -79.07% | 23.87% | 112.21% | — |
Corvus Pharmaceuticals, Inc. (CRVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Corvus Pharmaceuticals, Inc. (CRVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 22, 2026·SEC
Jun 12, 2026·SEC
Get notified when CRVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Corvus Pharmaceuticals, Inc. (CRVS) stock FAQ — growth, dividends, profitability & financials explained
No. Corvus Pharmaceuticals, Inc. (CRVS) reported a net loss of $64.3M over the trailing twelve months.
Corvus Pharmaceuticals, Inc. (CRVS) had a return on equity (ROE) of -35.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Corvus Pharmaceuticals, Inc. (CRVS) had negative free cash flow of $47.9M over the trailing twelve months.
